These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8727371)

  • 1. [Safer trials of vaccine and gene therapy against HIV].
    Ikuta K
    Hokkaido Igaku Zasshi; 1996 Jan; 71(1):21-6. PubMed ID: 8727371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus and acquired immunodeficiency syndrome: an update.
    Schnittman SM; Fauci AS
    Adv Intern Med; 1994; 39():305-55. PubMed ID: 8140958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.
    Jacobson JM; Pat Bucy R; Spritzler J; Saag MS; Eron JJ; Coombs RW; Wang R; Fox L; Johnson VA; Cu-Uvin S; Cohn SE; Mildvan D; O'Neill D; Janik J; Purdue L; O'Connor DK; Vita CD; Frank I;
    J Infect Dis; 2006 Sep; 194(5):623-32. PubMed ID: 16897661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal immunopathogenesis by SIV/HIV-1 (SHIV) containing a variant form of the HIV-1SF33 env gene in juvenile and newborn rhesus macaques.
    Luciw PA; Mandell CP; Himathongkham S; Li J; Low TA; Schmidt KA; Shaw KE; Cheng-Mayer C
    Virology; 1999 Oct; 263(1):112-27. PubMed ID: 10544087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of HIV-1 replication in elite suppressors.
    Blankson JN
    Discov Med; 2010 Mar; 9(46):261-6. PubMed ID: 20350494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of an oral therapeutic HIV-1 vaccine on AIDS patients with CD4 count above 250 cells/mm3.
    Jirathitikal V; Bourinbaiar AS
    Acta Virol; 2004; 48(2):73-8. PubMed ID: 15462281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gradual shutdown of virus production resulting in latency is the norm during the chronic phase of human immunodeficiency virus replication and differential rates and mechanisms of shutdown are determined by viral sequences.
    Li XD; Moore B; Cloyd MW
    Virology; 1996 Nov; 225(1):196-212. PubMed ID: 8918547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro induction of HIV-1 replication in resting CD4(+) T cells derived from individuals with undetectable plasma viremia upon stimulation with human T-cell leukemia virus type I.
    Moriuchi H; Moriuchi M
    Virology; 2000 Dec; 278(2):514-9. PubMed ID: 11118373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.
    Schooley RT; Spino C; Kuritzkes D; Walker BD; Valentine FA; Hirsch MS; Cooney E; Friedland G; Kundu S; Merigan TC; McElrath MJ; Collier A; Plaeger S; Mitsuyasu R; Kahn J; Haslett P; Uherova P; deGruttola V; Chiu S; Zhang B; Jones G; Bell D; Ketter N; Twadell T; Chernoff D; Rosandich M
    J Infect Dis; 2000 Nov; 182(5):1357-64. PubMed ID: 11023459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro reactivation of human immunodeficiency virus 1 from latently infected, resting CD4+ T cells after bacterial stimulation.
    Moriuchi H; Moriuchi M; Mizell SB; Ehler LA; Fauci AS
    J Infect Dis; 2000 Jun; 181(6):2041-4. PubMed ID: 10837189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.
    Maggiorella MT; Baroncelli S; Michelini Z; Fanales-Belasio E; Moretti S; Sernicola L; Cara A; Negri DR; Buttò S; Fiorelli V; Tripiciano A; Scoglio A; Caputo A; Borsetti A; Ridolfi B; Bona R; ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Ciccozzi M; Heeney J; Titti F; Cafaro A; Ensoli B
    Vaccine; 2004 Sep; 22(25-26):3258-69. PubMed ID: 15308348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A stochastic model for early HIV-1 population dynamics.
    Tuckwell HC; Le Corfec E
    J Theor Biol; 1998 Dec; 195(4):451-63. PubMed ID: 9837702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular basis for HIV infection: implication for the therapy].
    Nakaya T; Fujinaga K; Nishino Y; Kishi M; Ikuta K
    Tanpakushitsu Kakusan Koso; 1994 Jun; 39(8):1411-24. PubMed ID: 8016374
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
    Chun TW; Carruth L; Finzi D; Shen X; DiGiuseppe JA; Taylor H; Hermankova M; Chadwick K; Margolick J; Quinn TC; Kuo YH; Brookmeyer R; Zeiger MA; Barditch-Crovo P; Siliciano RF
    Nature; 1997 May; 387(6629):183-8. PubMed ID: 9144289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.
    Carcelain G; Tubiana R; Samri A; Calvez V; Delaugerre C; Agut H; Katlama C; Autran B
    J Virol; 2001 Jan; 75(1):234-41. PubMed ID: 11119593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.
    Birx DL; Loomis-Price LD; Aronson N; Brundage J; Davis C; Deyton L; Garner R; Gordin F; Henry D; Holloway W; Kerkering T; Luskin-Hawk R; McNeil J; Michael N; Foster Pierce P; Poretz D; Ratto-Kim S; Renzullo P; Ruiz N; Sitz K; Smith G; Tacket C; Thompson M; Tramont E; Yangco B; Yarrish R; Redfield RR
    J Infect Dis; 2000 Mar; 181(3):881-9. PubMed ID: 10720508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biology of HIV-1 and treatment strategies.
    Terwilliger EF
    Emerg Med Clin North Am; 1995 Feb; 13(1):27-42. PubMed ID: 7851319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
    Pippi F
    Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals.
    Chun TW; Justement JS; Lempicki RA; Yang J; Dennis G; Hallahan CW; Sanford C; Pandya P; Liu S; McLaughlin M; Ehler LA; Moir S; Fauci AS
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1908-13. PubMed ID: 12552096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.